Alprazolam ( DrugBank: Alprazolam )
2 diseases
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
8 | ハンチントン病 | 1 |
75 | クッシング病 | 1 |
8. ハンチントン病
臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00975481 (ClinicalTrials.gov) | October 2009 | 10/9/2009 | A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | A Randomized, Double-Blind, Placebo- And Active-Controlled Single-Dose, Crossover Study To Evaluate The Abuse Potential Of Single Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users | Alzheimer's Disease;Huntington's Disease | Drug: dimebon;Drug: placebo;Drug: alprazolam | Pfizer | Medivation, Inc. | Completed | 18 Years | 55 Years | All | 36 | Phase 1 | Canada |
75. クッシング病
臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | JPRN-jRCT1021210011 | 10/06/2021 | 10/06/2021 | A diagnosis of pseudo-Cushing's syndrome using dexamethason/CHR and Alprazolam | A diagnosis of pseudo-Cushing's syndrome using dexamethason/CRH and anxiolytic Alprazolam | Pseudo Cushing's Syndrome Glucocorticoid , Stress, dexamethasone suppression test;D003480 | In patients suspected of having Cushing's syndrome or pseudo-Cushing's syndrome, we perform two loading tests, DEX/CRH and alprazolam tests, in order to confirm the differential ability of this test. | Asari Yuko | NULL | Recruiting | Not applicable | Not applicable | Both | 100 | Phase 2 | Japan |